The probiotic supplements market is projected to expand from USD 13.50 billion in 2025 to USD 34.08 billion by 2035, registering a robust CAGR of 9.7% during this period. This growth is fueled by increasing consumer awareness of gut health, immunity, and the gut-brain axis. The rising prevalence of digestive disorders and a shift towards preventive healthcare have further propelled the demand for probiotic supplements.
Regulatory endorsements, such as health claims approved by the USA FDA and the European Food Safety Authority (EFSA) for strains like Lactobacillus and Bifidobacterium, have bolstered consumer confidence and product development. In the Asia-Pacific region, traditional consumption of fermented foods combined with rising disposable incomes has led to significant industry growth. Moreover, the proliferation of e-commerce platforms has enhanced accessibility, particularly for vegan, non-GMO, and allergen-free probiotic products.
Innovation remains a cornerstone for leading manufacturers. In 2024, Nestlé Health Science CEO Greg Behar emphasized the company's investment in synbiotic formulations that combine probiotics and prebiotics to deliver targeted digestive and immune benefits. ADM expanded its microbiome innovation center in Valencia to advance postbiotic product pipelines. The popularity of functional beverages, gummies, and chewables is on the rise, especially among pediatric and elderly populations in Europe and North America.
Traceability and evidence-based formulations are becoming industry standards. In 2025, Chr. Hansen launched a transparency platform providing QR-based verification of strain origin, colony-forming unit (CFU) count, and clinical backing. Consumer Lab's 2024 review recognized BioGaia and Culturelle for consistent potency and label accuracy. According to the International Probiotics Association (IPA), demand for shelf-stable and targeted-release capsules is projected to account for nearly 50% of sales by 2035.Emerging application areas include weight management and mental wellness. As consumers increasingly seek science-backed, clean-label products, probiotic supplements are poised to become integral to daily preventive healthcare routines.
The industry has been comprehensively analyzed across several key segmentation parameters. By customer orientation with respect to functionality, the study covers baby/infant (digestive health, metabolic health, immune support, and others), women (digestive health, gut brain axis, metabolic health, and others), men (digestive health, gut brain axis, metabolic health, and others), and unisex (digestive health, gut brain axis, metabolic health, and others).
By bacteria type, the industry is segmented into Lactobacillus, Streptococcus, Bifidobacterium, Bacillus coagulants, Saccharomyces, and Lactococcuslactis. Based on CFU count, the segments include less than 1 billion, 1 billion to 5 billion, 5 billion to 10 billion, 10 billion to 20 billion, 20 billion to 30 billion, 30 billion to 50 billion, and more than 50 billion.
By form, the industry is categorized into tablets/pills, capsules, liquid, powder, gummies/chewable, lozenges, and others (gels, soft gels). From the regional standpoint, the market is divided into North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Central Asia, Russia and Belarus, Balkan & Baltic Countries, and Middle East and Africa.
Based on a comprehensive analysis of the industry, the baby/infant digestive health segment emerges as the most lucrative, projected to grow at a CAGR of 12.3% from 2025 to 2035.This growth is driven by increasing awareness of early-life gut health, rising demand for pediatric nutrition solutions, and the incorporation of probiotics in infant formulas and supplements. The segment's expansion is further supported by healthcare professionals' recommendations and parental focus on preventive healthcare for infants.
The women's gut-brain axis segment is also poised for significant growth, with an anticipated CAGR of 11.5%during the same period. This is attributed to the growing recognition of the gut-brain connection, hormonal influences on gut health, and the prevalence of stress-related digestive issues among women. Product innovations targeting mood regulation and hormonal balance are expected to bolster this segment.
In the men's metabolic health segment, a CAGR of 10.8% is forecasted, driven by increasing concerns over metabolic disorders, obesity, and cardiovascular health among men. Probiotic formulations aimed at improving metabolic parameters and supporting weight management are gaining traction in this demographic.
The unisex immune support segment is projected to grow at a CAGR of 10.2%, fueled by heightened awareness of immune health across all age groups, especially in the wake of global health challenges. The demand for general wellness products that enhance immune function is contributing to this segment's expansion.
Other segments, such as women's digestive health and men's gut-brain Axis, are expected to experience steady growth, with CAGRs of 9.7% and 9.2%, respectively. These segments benefit from ongoing research into gender-specific health needs and the development of targeted probiotic solutions.
Lactobacillus-based products are expected to remain the dominant and most lucrative segment, projected to reach an industry value of USD 12.74 billion by 2035, up from USD 4.68 billion in 2025, growing at a CAGR of 10.6%. The segment’s sustained lead is driven by its extensive clinical validation across digestive, immune, and metabolic health applications, coupled with its high survivability in acidic environments and compatibility with various delivery forms. Lactobacillus strains such as Lrhamnosus and L. acidophilus are extensively used in both single- and multi-strain formulations, especially in women's health and pediatric applications.
Bifido bacteria follows as the second-largest segment, forecasted to grow at a CAGR of 9.8% between 2025 and 2035. Its rising application in infant gut health and elderly nutrition due to its colonization in the large intestine and role in fiber fermentation, supports long-term growth. The segment is projected to reach USD 7.83 billion by 2035, up from USD 3.01 billion in 2025.
Bacillus coagulants, a spore-forming strain known for heat resistance and shelf stability, is gaining momentum, particularly in functional foods and tropical climate geographies. The segment is forecasted to expand at 10.3% CAGR, reaching USD 5.64 billion by 2035.
Saccharomyces, primarily S. boulardii, is gaining attention for its proven efficacy in diarrhea management and antibiotic-associated gut disorders. Though a smaller base, it is poised for 9.1% CAGR, reaching USD 3.09 billion by 2035.
Streptococcus and Lactococcuslactis are niche but stable segments, especially in oral and dental health, with respective CAGRs of 7.6% and 7.2%. Collectively, these bacteria types contribute to the portfolio diversification and functional expansion of probiotic supplements globally.
In the industry, products containing 10 Billion to 20 Billion CFU are poised to be the most lucrative, driven by a balance of clinical efficacy, formulation stability, and consumer trust. This segment is expected to grow from USD 2.84 billion in 2025 to USD 7.62 billion by 2035, registering a CAGR of 10.4%. These doses align with most evidence-based recommendations for daily gut and immune support, particularly for general wellness and digestive health, making them the preferred choice in retail and healthcare channels.
The 5 Billion to 10 Billion CFU segment follows closely, projected to grow at a CAGR of 9.9%, with industry value rising from USD 2.31 billion in 2025 to USD 6.03 billion by 2035. This category is widely used in women’s health and children’s probiotics, where moderate potency meets safety and palatability requirements.
More than 50 Billion CFU formulations are gaining momentum among clinical practitioners and performance-focused consumers. Despite a smaller base, this segment is forecasted to expand at a CAGR of 11.1%, reaching USD 4.12 billion by 2035, from USD 1.42 billion in 2025. The growth is primarily fueled by demand in high-strength probiotics for metabolic support, antibiotic recovery, and competitive athletic performance.
1 Billion to 5 Billion CFU remains a mass-industry staple, especially in chewables, gummies, and fortified drinks. It will grow steadily at 8.7% CAGR, while Less than 1 Billion CFU typically used in functional snacks and beverages will grow slower at 6.2% CAGR due to limited therapeutic potency.
Emerging segments like 20 Billion to 30 Billion CFU and 30 Billion to 50 Billion CFU are expected to gain ground among chronic health users, with CAGRs of 10.0% and 10.2%, respectively, as formulation capabilities improve and consumer understanding of CFU thresholds matures.
In the industry, capsules are projected to be the most lucrative form, expanding from USD 4.26 billion in 2025 to USD 11.29 billion by 2035, at a robust CAGR of 10.2%. Capsules offer optimal protection of probiotic strains through enteric coatings and delayed-release technologies, which enhance viability through gastrointestinal transit. Their convenience, dosage precision, and shelf stability make them the dominant delivery form in clinical and retail channels, particularly in adult and elderly populations.
Gummies and chewables follow closely, driven by rising consumer preference for palatable, non-pill formats, especially among children and millennials. This segment is forecast to grow at 10.6% CAGR, reaching USD 8.12 billion by 2035, up from USD 2.95 billion in 2025. The combination of flavor, ease of consumption, and product innovation (e.g., sugar-free and vegan gummies) makes this format particularly attractive for preventive wellness buyers.
Powdered probiotics favored for flexibility in dosing and incorporation into foods and beverages will scale from USD 2.74 billion in 2025 to USD 6.82 billion by 2035, registering a CAGR of 9.4%. Growth is concentrated in APAC and sports nutrition industries.
Liquid formulations, while limited by cold-chain requirements and lower shelf life, will still post a CAGR of 8.2%, driven by adoption in pediatric and geriatric care. Tablets and pills, despite their legacy presence, are showing signs of stagnation, expected to grow at a modest 6.8% CAGR, primarily retained in pharmacy-based sales.
Lozenges are gaining niche traction in oral and dental health use-cases, forecast to grow at 8.9% CAGR, while gels and soft gels used for multi-functional or combined delivery systems are projected at 9.1% CAGR, especially in high-CFU formulations targeting gut-brain axis and immune health.
Probiotic Supplements Industry Forecast by Top Countries
South Korea’s industry is set to grow from USD 612 million in 2025 to USD 1.61 billion by 2035, registering a CAGR of 10.1%. Known for its tech-savvy consumers and nutraceutical acceptance, South Korea has seen probiotics evolve from digestive aids to holistic wellness products targeting skin, mood, and metabolic health. The Ministry of Food and Drug Safety (MFDS) governs the probiotic space, with clear guidelines for functional claims and strain documentation, ensuring that clinically supported products receive higher consumer trust.
Korean consumers show a strong preference for powder sticks, granules, and chewable tablets formats aligned with the convenience-centric lifestyle. Domestic brands like CJ CheilJedang and Chong Kun Dang dominate through robust retail partnerships and digital health platforms, while international players focus on urban centers and e-commerce. Beauty-from-within is a unique growth lever, with probiotics increasingly marketed for skin clarity, hormonal balance, and stress resilience in women aged 20-40.
The convergence of K-beauty, digital therapeutics, and functional nutrition is creating hybrid probiotic offerings that appeal across gender and age cohorts. Probiotic pairing with collagen, fiber, and herbal adaptogens is also gaining popularity. Distribution is multi-channel, with D2C platforms, health-focused apps, and pharmacy chains driving discovery and repeat purchase. With favorable regulatory clarity, advanced packaging technology, and rapid product cycling, South Korea remains a high-margin, innovation-led industry.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 10.1% |
Brazil’s industry is forecast to grow from USD 584 million in 2025 to USD 1.51 billion by 2035, reflecting a CAGR of 9.8%. As the leading Latin American industry, Brazil’s probiotic sector is driven by rising digestive issues, immune challenges, and growing self-care trends among urban consumers. The National Health Surveillance Agency (ANVISA) regulates probiotics under functional food and supplement categories, emphasizing safety and strain-level identification.
Pharmacy chains such as RaiaDrogasil and PagueMenos play a central role in probiotic retailing, supported by growing e-commerce platforms. Functional yogurts and sachet supplements are prevalent in low- and middle-income segments, while capsules and chewables are expanding in high-income urban clusters. Brands like Vitafor and Nestlé lead with localized formulations tailored for digestive and immune support.
Brazil’s regulatory environment is increasingly harmonizing with global standards, encouraging foreign direct investment and import partnerships. Pediatric and maternal probiotic solutions are emerging verticals, reflecting the younger demographic profile. Regional disparities in health access create variation in penetration, but mobile health campaigns and community pharmacies are bridging the gap. Brazil’s industry offers scale,
| Country | CAGR (2025 to 2035) |
|---|---|
| Brazil | 9.8% |
The UK industry is anticipated to expand from USD 725 million in 2025 to USD 1.66 billion by 2035, registering a CAGR of 8.7%. The country’s high consumer receptiveness to digestive health solutions and gut-brain wellness has made it a fast-growing European hub for probiotic innovation. Post-Brexit divergence from EU health claim regulations has created both opportunities and challenges while companies enjoy more marketing flexibility, they also face heightened responsibility to validate scientific claims under the MHRA and ASA frameworks.
Pharmacies like Boots and Holland & Barrett dominate the physical retail space, but D2C brands have carved a niche in the premium segment. Brands such as Symprove, Optibac, and Bio-Kult have gained prominence for clinically supported formulations tailored for IBS, immunity, and mental well-being. Consumer preference leans toward capsule and liquid formats, with increasing acceptance of high-CFU products and multi-strain blends. In urban centers, probiotics are frequently recommended by nutritionists and general practitioners, contributing to trust and adoption.
Digital awareness campaigns around gut microbiome health and mental resilience have elevated category interest among Gen Z and millennial demographics. The UK's focus on clean-label, allergen-free, and vegan probiotic solutions is accelerating product differentiation. With growing alignment between clinical research and functional nutrition, the UK market is well-positioned for continued value-based expansion.
| Country | CAGR (2025 to 2035) |
|---|---|
| United Kingdom | 8.7% |
Canada's industry is projected to grow from USD 648 million in 2025 to USD 1.52 billion by 2035, with a CAGR of 8.9%. Health Canada regulates probiotics under the Natural Health Product (NHP) framework, which enforces strict guidelines on efficacy and CFU content, lending strong credibility to products available in the industry. The combination of clinical claims with consumer education has built a well-informed buyer base that values safety and science.
The Canadian industry is dominated by capsules and softgels, with expanding interest in functional formats such as powders, gummies, and drinkables. Brands like Jamieson, Renew Life, and Genuine Health hold strong industry positions in pharmacies and grocery stores. E-commerce is gaining traction, with health-focused platforms and personalized wellness brands leveraging digital marketing to reach tech-savvy consumers.
Probiotics in Canada are largely positioned around digestive balance, immunity, and antibiotic-associated gut recovery. There is also emerging demand in women's health, children’s formulations, and gut-brain products. Cross-border buying from the USA introduces competitive pricing pressures, but also exposes the industry to global innovation. Canada's multicultural dietary habits, strong regulatory enforcement, and aging population combine to create a favorable environment for long-term probiotic adoption.
| Country | CAGR (2025 to 2035) |
|---|---|
| Canada | 8.9% |
India’s industry is projected to expand from USD 790 million in 2025 to USD 2.48 billion by 2035, achieving a CAGR of 12.1% the highest among top-tier economies. The growth trajectory is fueled by a combination of rising gastrointestinal disorders, antibiotic overuse, and increasing lifestyle-related metabolic diseases. As a country transitioning toward preventive care, India has seen a significant uptick in demand for probiotics across urban centers and gradually into Tier 2 cities, where awareness is rising rapidly. The country's youthful population and rising internet penetration have allowed e-commerce-based nutraceutical sales to flourish.
FSSAI regulates probiotic supplements under the nutraceutical category, and recent reforms are aiming to introduce more rigorous checks on label accuracy and CFU integrity. However, the current regime still allows significant flexibility for new product entries. Domestic companies such as Himalaya Wellness, ZydusNutriva, and Dr. Reddy’s Laboratories are scaling probiotic portfolios with India-centric claims around digestion, immunity, and detoxification. Meanwhile, multinationals like Abbott and Nestlé are expanding localized product lines through D2C channels and doctor-driven outreach programs.
Powder sachets, chewables, and capsules are the dominant formats. Pediatric applications and prenatal probiotic use cases are also gaining ground. India’s distinct advantage lies in its large addressable population, accelerating middle-class health spending, and strong pharmacy retail penetration. While industry fragmentation remains, consolidation is expected as established pharma players begin to integrate probiotics into therapeutic lines. India is structurally positioned to be one of the most scalable probiotic markets globally over the next decade.
| Country | CAGR (2025 to 2035) |
|---|---|
| India | 12.1% |
Germany's industry is expected to expand from USD 878 million in 2025 to USD 2.01 billion by 2035, growing at a CAGR of 8.6%. As Europe's largest economy, Germany plays a central role in shaping EU-wide supplement policy. Consumers exhibit high demand for natural, evidence-based products, particularly for gastrointestinal disorders, IBS, and antibiotic recovery. Capsules and lozenges dominate the industry, often sold via pharmacy channels where pharmacists serve as key gatekeepers of consumer trust.
The European Food Safety Authority (EFSA) maintains rigorous requirements for strain-specific health claims, significantly reducing the volume of unverified products in circulation. German manufacturers and importers are increasingly investing in clinical trials to meet these standards, especially for high-CFU and multi-strain probiotic formulations. Public insurance reimbursement for gut-related treatments that integrate probiotics has added to category legitimacy.
Online penetration has been slower than in Anglo industries but is accelerating post-COVID through platforms like DocMorris and ApothekenUmschau. The gut-brain axis and immune modulation remain the two strongest emerging verticals. German consumers also show growing interest in synbiotics and postbiotics as next-gen solutions. With high levels of compliance, science-driven formulation, and patient-pharmacist interaction, Germany is a benchmark for regulatory maturity and product integrity in Europe.
| Country | CAGR (2025 to 2035) |
|---|---|
| Germany | 8.6% |
The United States stands as the most mature and profitable industry for probiotic supplements globally, projected to grow from USD 3.92 billion in 2025 to USD 9.56 billion by 2035, registering a CAGR of 9.4%. The country benefits from an entrenched wellness culture and strong consumer inclination toward preventive healthcare. Probiotic use is widespread across age demographics, driven by rising awareness of gut health's link to immunity, mental well-being, and chronic disease prevention. The USA regulatory framework governed by the Dietary Supplement Health and Education Act (DSHEA) allows manufacturers to launch probiotic products with structure-function claims, without pre-industry approval, provided they meet labeling and safety standards. However, in recent years, the FDA has increased enforcement actions related to false CFU counts and misleading claims, resulting in elevated quality control and traceability across the value chain.
Digital distribution plays a pivotal role, with a surge in direct-to-consumer (D2C) platforms offering personalized probiotic regimes based on microbiome testing. Leading e-commerce channels such as Amazon, iHerb, and brand-owned storefronts enable quick industry access and data-driven product development. Innovation in formulation such as delayed-release capsules, shelf-stable spore-formers, and synbiotic blends is fueling premiumization. Key segments include digestive health, women's health (particularly for UTI and pH balance), immune support, and emerging gut-brain axis formulations for mood and cognition.
Clinical validation and doctor endorsements have enhanced consumer trust in high-CFU count products, particularly in the 10 to 20 billion range. M&A activity is robust, with larger nutraceutical players acquiring niche probiotic brands to capture high-margin segments. With high repeat usage, brand loyalty, and regulatory leniency balanced by increasing oversight, the USA industry offers a structurally favorable landscape for sustained growth.
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 9.4% |
China is poised to become the fastest-growing industry globally, projected to rise from USD 1.92 billion in 2025 to USD 5.76 billion by 2035, reflecting a CAGR of 11.4%. Rapid urbanization, rising middle-class incomes, and a growing focus on gut health have elevated demand for functional supplements. Chinese consumers are increasingly shifting from traditional medicine to modern, science-backed nutritional products, especially probiotics that support digestion, skin health, and immune resilience. Functional beverages, sachets, and powder sticks dominate format preference due to ease of integration into daily routines.
The regulatory landscape, overseen by the National Medical Products Administration (NMPA), is evolving with stricter enforcement on ingredient traceability, strain-specific efficacy, and CFU disclosure. This has narrowed the playing field to clinically supported formulations, benefitting multinational players with robust R&D pipelines. Yet, domestic champions like BY-HEALTH, Amway China, and Alibaba-backed brands are capturing growth by aligning formulations with traditional Chinese health concepts such as yin-yang balance and detoxification.
E-commerce plays a pivotal role, with platforms like JD Health, Tmall, and Xiaohongshu facilitating both B2C and influencer-driven awareness campaigns. A growing niche in baby/infant probiotics and women’s metabolic wellness products is emerging, further diversifying the industry. With increasing health literacy and digital access across Tier 2 and Tier 3 cities, the long-term potential for category penetration remains substantial. China's blend of cultural readiness, rising clinical standards, and tech-enabled distribution makes it one of the most attractive destinations for probiotic investments globally.
| Country | CAGR (2025 to 2035) |
|---|---|
| China | 11.4% |
Japan’s probiotic supplements industry is forecast to grow from USD 1.31 billion in 2025 to USD 2.99 billion by 2035, registering a CAGR of 8.4%. As one of the earliest adopters of probiotic-integrated foods and supplements, Japan has a deeply embedded culture of microbiota-focused wellness, with traditional staples like natto, miso, and yogurt reinforcing daily usage. High health literacy and a rapidly aging population have created robust demand for gut and metabolic health products. Japanese consumers also prioritize product transparency and safety, making regulatory compliance a key industry enabler.
Regulatory oversight is administered by the Consumer Affairs Agency (CAA) through the Foods with Functional Claims (FFC) program, requiring manufacturers to provide scientific substantiation for probiotic benefits. This regulatory rigor has helped filter out non-credible products, thereby increasing consumer trust. Leading domestic brands like Yakult, Meiji, and Kirin continue to dominate, with a recent surge in research-backed gut-brain axis formulations, particularly targeting stress, anxiety, and cognitive performance.
Japan’s pharmacy-first channel structure is complemented by digital growth across health-focused platforms and specialty e-commerce. Drinkable formats and sachets are preferred over pills, especially among elderly users. With its strong scientific orientation, clinical trial ecosystem, and consumer loyalty to time-tested probiotic strains, Japan remains a stable, value-driven industry ideal for premium offerings.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 8.4% |
Culturelle (i-Health, Inc./DSM-Firmenich)
Culturelle, under i-Health Inc., a subsidiary of DSM-Firmenich, commands a significant presence in the probiotic supplements industry. Leveraging the clinically studied Lactobacillus rhamnosus GG strain, Culturelle offers a range of products targeting digestive health, immune support, and overall wellness. Their commitment to quality and science-backed formulations has solidified their reputation among consumers and healthcare professionals alike
Align (Procter & Gamble)
Align, a brand by Procter & Gamble, is renowned for its Bifidobacterium 35624 strain, catering primarily to digestive health. With strong endorsements from gastroenterologists and a focus on clinical efficacy, Align has established itself as a trusted choice among consumers seeking targeted probiotic solutions. Its presence is notably strong in North America, where it benefits from P&G's extensive distribution networks.
Billion Cheers (Fermentis Life Sciences Pvt Ltd)
Billion Cheers, an Indian brand by Ferment is Life Sciences, has rapidly gained traction in the domestic industry. Offering high-CFU count products, including women's health-focused formulations, Billion Cheers addresses specific consumer needs with innovative delivery formats like ready-to-drink powders. Their emphasis on localized solutions and affordability positions them favorably among Indian consumers.
Digestive Advantage (Schiff Vitamins/Reckitt Benckiser)
Digestive Advantage, under Schiff Vitamins and owned by Reckitt Benckiser, differentiates itself with products designed for enhanced survivability through the digestive tract.Their use of patented strains and focus on digestive and immune health has garnered a loyal customer base.The brand's presence is bolstered by availability in major retail outlets and a variety of product formats, including gummies and capsules.
Garden of Life (Nestlé Health Science)
Garden of Life, part of Nestlé Health Science, emphasizes organic, non-GMO, and whole-food-based probiotic supplements. Their extensive product line caters to various demographics, including targeted solutions for women, men, and seniors.With a commitment to clean-label products and sustainability, Garden of Life appeals to health-conscious consumers seeking premium probiotic options.
| Attribute | Details |
|---|---|
| Current Total Market Size (2025) | USD 13.50 billion |
| Projected Market Size (2035) | USD 34.08 billion |
| CAGR (2025 to 2035) | 9.7% |
| Base Year for Estimation | 2024 |
| Historical Period | 2020 to 2024 |
| Projections Period | 2025 to 2035 |
| Report Parameter | Revenue in USD billion/ Volume in Kilotons |
| By Customer Orientation w.r.t. Functionality | Baby/ Infant, Women, Men, Unisex |
| By Bacteria Type | Lactobacillus, Streptococcus, Bifidobacterium , Bacillus coagulans , Saccharomyces, Lactococcus lactis |
| By CFU Count | Less than 1 Billion, 1 Billion to 5 Billion, 5 Billion to 10 Billion, 10 Billion to 20 Billion, 20 Billion to 30 Billion, 30 Billion to 50 Billion, More than 50 Billion |
| By Form | Tablets / Pills, Capsules, Liquid, Powder, Gummies / Chewable, Lozenges, Others (Gels, Soft Gels) |
| Regions Covered | North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Central Asia, Russia and Belarus, Balkan & Baltic Countries, Middle East and Africa |
| Countries Covered | United States, China, Germany, Japan, India, United Kingdom, France, Italy, South Korea |
| Key Players | Culturelle ( i -Health, Inc.), Align, Billion Cheers ( Fermentis Life Sciences Pvt Ltd), Digestive Advantage, Garden of Life (Nestle SA), Spring Valley, Now Foods, Nature Made, HUM Nutrition Inc., OLLY, Other Market Players |
| Additional Attributes | Dollar sales by value, market share analysis by region, and country-wise analysis |
| Customization and Pricing | Available on request |
The industry is poised to reach USD 13.50 billion in 2025.
The industry is slated to register USD 34.08 billion by 2035.
Products for baby/infant digestive health are widely consumed.
India, slated to grow at 12.1% CAGR during the study period, is poised for the fastest growth.
Key companies include Culturelle (i-Health, Inc.), Align, Billion Cheers (Fermentis Life Sciences Pvt Ltd), Digestive Advantage, Garden of Life (Nestle SA), Spring Valley, Now Foods, Nature Made, HUM Nutrition Inc., OLLY, Other Market Players
Explore Food Supplement and Nutrition Insights
Probiotic Supplements Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
